Incidence and risk factors of cardiovascular mortality in patients with gastrointestinal adenocarcinoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
04
2021
accepted:
15
12
2021
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
1
2
2023
Statut:
epublish
Résumé
Gastrointestinal (GI) cancers are common and fatal. Improved cancer-directed therapies, with thier substantial role in improving cancer-specific survival, may increase non-cancer mortality-including cardiovascular mortality-in these patients. To identify the risk factors of cardiovascular mortality in GI adenocarcinoma patients. Data of GI adenocarcinoma patients were gathered from the Surveillance, Epidemiology, and End Results database. We used Pearson's chi-square test to assess the relationships between categorical variables. We used the Kaplan-Meyer test in the univariate analysis and Cox regression test for the multivariate analysis. Among 556,350 included patients, 275,118 (49.6%) died due to adenocarcinoma, 64,079 (11.5%) died due to cardiovascular causes, and 83,161 (14.9%) died due to other causes. Higher rates of cardiovascular mortality were found in patients ≥ 50 years (HR, 8.476; 95% CI, 7.91-9.083), separated (HR, 1.27; 95% CI, 1.184-1.361) and widowed (HR, 1.867; 95% CI, 1.812-1.924), patients with gastric (HR, 1.18; 95% CI, 1.1-1.265) or colorectal AC (HR, 1.123; 95% CI, 1.053-1.198), and patients not undergone surgery (HR, 2.04; 95% CI, 1.958-2.126). Lower risk patients include females (HR, 0.729; 95% CI, 0.717-0.742), blacks (HR, 0.95; 95% CI, 0.924-0.978), married (HR, 0.77; 95% CI, 0.749-0.792), divorced (HR, 0.841; 95% CI, 0.807-0.877), patients with pancreatic AC (HR, 0.83; 95% CI, 0.757-0.91), and patients treated with chemotherapy (HR, 0.416; 95% CI, 0.406-0.427). Risk factors for cardiovascular mortality in GI adenocarcinoma include advanced age, males, whites, separated and widowed, gastric or colorectal adenocarcinoma, advanced grade or advanced stage of the disease, no chemotherapy, and no surgery. Married and divorced, and patients with pancreatic adenocarcinoma have a lower risk.
Sections du résumé
BACKGROUND
Gastrointestinal (GI) cancers are common and fatal. Improved cancer-directed therapies, with thier substantial role in improving cancer-specific survival, may increase non-cancer mortality-including cardiovascular mortality-in these patients.
AIM
To identify the risk factors of cardiovascular mortality in GI adenocarcinoma patients.
METHODS
Data of GI adenocarcinoma patients were gathered from the Surveillance, Epidemiology, and End Results database. We used Pearson's chi-square test to assess the relationships between categorical variables. We used the Kaplan-Meyer test in the univariate analysis and Cox regression test for the multivariate analysis.
RESULTS
Among 556,350 included patients, 275,118 (49.6%) died due to adenocarcinoma, 64,079 (11.5%) died due to cardiovascular causes, and 83,161 (14.9%) died due to other causes. Higher rates of cardiovascular mortality were found in patients ≥ 50 years (HR, 8.476; 95% CI, 7.91-9.083), separated (HR, 1.27; 95% CI, 1.184-1.361) and widowed (HR, 1.867; 95% CI, 1.812-1.924), patients with gastric (HR, 1.18; 95% CI, 1.1-1.265) or colorectal AC (HR, 1.123; 95% CI, 1.053-1.198), and patients not undergone surgery (HR, 2.04; 95% CI, 1.958-2.126). Lower risk patients include females (HR, 0.729; 95% CI, 0.717-0.742), blacks (HR, 0.95; 95% CI, 0.924-0.978), married (HR, 0.77; 95% CI, 0.749-0.792), divorced (HR, 0.841; 95% CI, 0.807-0.877), patients with pancreatic AC (HR, 0.83; 95% CI, 0.757-0.91), and patients treated with chemotherapy (HR, 0.416; 95% CI, 0.406-0.427).
CONCLUSIONS
Risk factors for cardiovascular mortality in GI adenocarcinoma include advanced age, males, whites, separated and widowed, gastric or colorectal adenocarcinoma, advanced grade or advanced stage of the disease, no chemotherapy, and no surgery. Married and divorced, and patients with pancreatic adenocarcinoma have a lower risk.
Identifiants
pubmed: 36706093
doi: 10.1371/journal.pone.0262013
pii: PONE-D-21-11463
pmc: PMC9882755
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0262013Informations de copyright
Copyright: © 2023 Nso et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Clin Oncol. 2021 Feb;26(2):387-398
pubmed: 33113018
Mayo Clin Proc. 2014 Sep;89(9):1287-306
pubmed: 25192616
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Aging (Albany NY). 2020 Nov 28;12(22):22927-22948
pubmed: 33289707
Clin Liver Dis. 2015 May;19(2):223-38
pubmed: 25921660
BMC Cancer. 2018 Jun 25;18(1):688
pubmed: 29940910
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2016 Jul 1;34(19):2239-46
pubmed: 27091709
Methods Mol Biol. 2007;404:273-301
pubmed: 18450055
Annu Rev Med. 2016;67:103-17
pubmed: 26473416
JAMA. 1991 Sep 25;266(12):1672-7
pubmed: 1886191
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46
pubmed: 26112199
J Am Soc Echocardiogr. 2011 Mar;24(3):229-67
pubmed: 21338862
Prz Gastroenterol. 2018;13(2):109-117
pubmed: 30002769
J Gastrointest Oncol. 2020 Apr;11(2):269-276
pubmed: 32399268
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Cancer Causes Control. 2013 Jun;24(6):1207-22
pubmed: 23563998
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Ann Cardiothorac Surg. 2017 Mar;6(2):190
pubmed: 28447010
Sci Rep. 2018 May 21;8(1):7940
pubmed: 29786691
Int J Clin Oncol. 2019 May;24(5):501-507
pubmed: 30604158
Biochem Med (Zagreb). 2013;23(2):143-9
pubmed: 23894860
Circulation. 2017 Apr 11;135(15):1388-1396
pubmed: 28132957
Circulation. 2016 Nov 15;134(20):1519-1531
pubmed: 27821538
Am J Surg. 2019 Jan;217(1):103-107
pubmed: 29807632
Circ Res. 2016 Mar 18;118(6):1008-20
pubmed: 26987914
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79
pubmed: 18812549
Int J Cancer. 2016 Dec 1;139(11):2436-46
pubmed: 27522007
Medicine (Baltimore). 2020 Jul 31;99(31):e21322
pubmed: 32756116
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57
pubmed: 27664261
J Cancer Surviv. 2013 Jun;7(2):253-61
pubmed: 23417882
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Cancer. 2019 Jun 15;125(12):2107-2114
pubmed: 30892701
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
CA Cancer J Clin. 2016 Jul;66(4):309-25
pubmed: 26919165
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Dis Colon Rectum. 2016 Apr;59(4):306-15
pubmed: 26953989
Br J Cancer. 2003 Jul 21;89(2):232-8
pubmed: 12865907
Cancer. 2016 Apr 1;122(7):1009-16
pubmed: 26848927
Curr Atheroscler Rep. 2015 Mar;17(3):484
pubmed: 25637040
Hellenic J Cardiol. 2017 May - Jun;58(3):215-219
pubmed: 28258825
J Natl Compr Canc Netw. 2018 Jan;16(1):66-97
pubmed: 29295883